Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
$11.83
-$0.14(-3.78%)
At close: 4:00 PM EST
$11.83
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$2.60 - $16.96
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.36M
Market Cap
$1.30B
Enterprise Value$930.34M
Total Cash (Recent Filing)$343.99M
Total Debt (Recent Filing)$5.93M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Apr 01, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding109,819,570
10 Day Avg. Volume1,389,862
30 Day Avg. Volume1,357,783
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.56
Price to Sales (P/S)2.95
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue-1.40K
Enterprise Value/Gross Profit-45.03
Enterprise Value/Ebitda-6.05
Forecast
1Y Price Target
$20.14Price Target Upside70.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2b results showed a marked reduction in severe hypoglycemic events, supporting avexitide's potential to become the first approved therapy for post-bariatric hypoglycemia.
Pipeline Diversification And Near-term CatalystsAMX0114's novel antisense approach in ALS, combined with Fast Track designation and expected safety and biomarker readouts in the first half of 2026, could validate a differentiated mechanism and broaden the company's pipeline.
Regulatory And Commercial PotentialBreakthrough Therapy and Orphan Drug designations for avexitide support expedited review pathways and the potential for premium pricing and rapid market uptake if approved.
Bears Say
Financing RiskHigh cash burn and a limited cash runway create material financing risk that may necessitate dilutive capital raises and pressure the stock.
Market Sentiment And PositioningElevated short interest of around 13% of the float indicates notable bearish sentiment and the potential for continued downside pressure or increased volatility.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $2.60 and its highest was $16.96 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $1.30B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Apr 01, 2026 which is in 80 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.436 by $0.066.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.35.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 109,819,570 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.436. Following the earnings report the stock price went down -5.891%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.14 (70.25% Upside)
$20.14 (70.25% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $201.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
213.79%
12-Months-Change
Fundamentals
Return on Equity
-56.52%
Trailing 12-Months
Asset Growth
44.68%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong financial performance and progress across multiple programs. However, there is a noted delay in the LUCIDITY trial enrollment, indicating some operational challenges. The urgency and unmet need in the PBH market further underscore the importance of avexitide's development.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$20.14
▲(70.25% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
7.45% Insiders
12.01% Mutual Funds
55.54% Other Institutional Investors
10.69% Public Companies and Individual Investors